Document is current
Any future updates will be listed below
-
Authors
Uddin, Md Mesbah https://orcid.org/0000-0003-1846-0411
Saadatagah, Seyedmohammad
Niroula, Abhishek
Yu, Bing https://orcid.org/0000-0003-4818-1077
Hornsby, Whitney E.
Ganesh, Shriienidhie https://orcid.org/0000-0002-4226-7526
Lannery, Kim
Schuermans, Art
Honigberg, Michael C. https://orcid.org/0000-0001-8630-5021
Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
Libby, Peter https://orcid.org/0000-0002-1502-502X
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Ballantyne, Christie M. https://orcid.org/0000-0002-6432-1730
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL148050)
Fondation Leducq (TNE-18CVD04)
P.N. is supported by a Hassenfeld Scholar Award and the Paul & Phyllis Fireman Endowed Chair in Vascular Medicine from the Massachusetts General Hospital.
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 1 September 2024
First Online: 9 September 2024
Competing interests
: M.C.H. reports research grants from Genentech, advisory board service for Miga Health, and consulting fees from Comanche Biopharma, all unrelated to the present work. P.L. is an unpaid consultant to/or involved in clinical trials for Amgen, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Novo Nordisk, Novartis, Sanofi-Regeneron. P.L. is a member of the scientific advisory board for Amgen, Caristo Diagnostics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, MedImmune, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Therapeutics, and XBiotech, Inc. P.L.’s laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk, and Genentech. P.L. is on the Board of Directors of XBiotech, Inc. P.L. has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. B.L.E. has received research funding from Novartis and Calico. He has received consulting fees from Abbvie. He is a member of the scientific advisory board and shareholder for Neomorph Inc., TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics, all distinct from the present work. P.N., A.G.B., and B.L.E. are scientific co-founders of TenSixteen Bio. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, Astra Zeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in MyOme, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. C.M.B. reports grant/research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA, consultation fees from Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, TenSixteen Bio. The remaining authors declare no competing interests.
